|
1
|
Gondivkar SM, Gadbail AR, Chole R and
Parikh RV: Adenoid cystic carcinoma: A rare clinical entity and
literature review. Oral Oncol. 47:231–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fordice J, Kershaw C, El-Naggar A and
Goepfert H: Adenoid cystic carcinoma of the head and neck:
Predictors of morbidity and mortality. Arch Otolaryngol Head Neck
Surg. 125:149–152. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ehrlich M: DNA hypomethylation in cancer
cells. Epigenomics. 1:239–259. 2009. View Article : Google Scholar
|
|
4
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Latham KE: X chromosome imprinting and
inactivation in the early mammalian embryo. Trends Genet.
12:134–138. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lyko F and Brown R: DNA methyltransferase
inhibitors and the development of epigenetic cancer therapies. J
Natl Cancer Inst. 97:1498–1506. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H,
Welsh W and Yang CS: Tea polyphenol (−)-epigallocatechin-3-gallate
inhibits DNA methyltransferase and reactivates methylation-silenced
genes in cancer cell lines. Cancer Res. 63:7563–7570.
2003.PubMed/NCBI
|
|
8
|
Shao C, Tan M, Bishop JA, Liu J, Bai W,
Gaykalova DA, Ogawa T, Vikani AR, Agrawal Y, Li RJ, et al:
Suprabasin is hypomethylated and associated with metastasis in
salivary adenoid cystic carcinoma. PLoS One. 7:e4855822012.
View Article : Google Scholar
|
|
9
|
Shao C, Sun W, Tan M, Glazer CA, Bhan S,
Zhong X, Fakhry C, Sharma R, Westra WH, Hoque MO, et al:
Integrated, genome-wide screening for hypomethylated oncogenes in
salivary gland adenoid cystic carcinoma. Clin Cancer Res.
17:4320–4330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fan X, Chen B, Xu J, Zhang H, Deng F and
Xiang X: Methylation status of the PTEN gene in adenoid cystic
carcinoma cells. Mol Med Rep. 3:775–779. 2010.
|
|
11
|
Daa T, Kashima K, Kondo Y, Yada N, Suzuki
M and Yokoyama S: Aberrant methylation in promoter regions of
cyclin-dependent kinase inhibitor genes in adenoid cystic carcinoma
of the salivary gland. APMIS. 116:21–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Williams MD, Chakravarti N, Kies MS,
Maruya S, Myers JN, Haviland JC, Weber RS, Lotan R and El-Naggar
AK: Implications of methylation patterns of cancer genes in
salivary gland tumors. Clin Cancer Res. 12:7353–7358. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Clark JC, Thomas DM, Choong PF and Dass
CR: RECK - a newly discovered inhibitor of metastasis with
prognostic significance in multiple forms of cancer. Cancer
Metastasis Rev. 26:675–683. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Masui T, Doi R, Koshiba T, Fujimoto K,
Tsuji S, Nakajima S, Koizumi M, Toyoda E, Tulachan S, Ito D, et al:
RECK expression in pancreatic cancer: Its correlation with lower
invasiveness and better prognosis. Clin Cancer Res. 9:1779–1784.
2003.PubMed/NCBI
|
|
15
|
Takemoto N, Tada M, Hida Y, Asano T, Cheng
S, Kuramae T, Hamada J, Miyamoto M, Kondo S and Moriuchi T: Low
expression of reversion-inducing cysteine-rich protein with Kazal
motifs (RECK) indicates a shorter survival after resection in
patients with adenocarcinoma of the lung. Lung Cancer. 58:376–383.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Figueira RC, Gomes LR, Neto JS, Silva FC,
Silva ID and Sogayar MC: Correlation between MMPs and their
inhibitors in breast cancer tumor tissue specimens and in cell
lines with different metastatic potential. BMC Cancer. 9:202009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang C, Ling Y, Xu Y, Gao L, Li R, Zhu J,
Fan L and Wei L: The silencing of RECK gene is associated with
promoter hypermethylation and poor survival in hepatocellular
carcinoma. Int J Biol Sci. 8:451–458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou X, Huang S, Jiang L, Zhang S, Li W,
Chen Z and Zhang D: Expression of RECK and MMP-2 in salivary
adenoid cystic carcinoma: Correlation with tumor progression and
patient prognosis. Oncol Lett. 7:1549–1555. 2014.PubMed/NCBI
|
|
19
|
Kato K, Long NK, Makita H, Toida M,
Yamashita T, Hatakeyama D, Hara A, Mori H and Shibata T: Effects of
green tea polyphenol on methylation status of RECK gene and cancer
cell invasion in oral squamous cell carcinoma cells. Br J Cancer.
99:647–654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oh J, Takahashi R, Kondo S, Mizoguchi A,
Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H,
Alexander DB, et al: The membrane-anchored MMP inhibitor RECK is a
key regulator of extracellular matrix integrity and angiogenesis.
Cell. 107:789–800. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Echizenya M, Kondo S, Takahashi R, Oh J,
Kawashima S, Kitayama H, Takahashi C and Noda M: The
membrane-anchored MMP-regulator RECK is a target of myogenic
regulatory factors. Oncogene. 24:5850–5857. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cho CY, Wang JH, Chang HC, Chang CK and
Hung WC: Epigenetic inactivation of the metastasis suppressor RECK
enhances invasion of human colon cancer cells. J Cell Physiol.
213:65–69. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang HC, Cho CY and Hung WC:
Downregulation of RECK by promoter methylation correlates with
lymph node metastasis in non-small cell lung cancer. Cancer Sci.
98:169–173. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hellebrekers DM, Griffioen AW and van
Engeland M: Dual targeting of epigenetic therapy in cancer. Biochim
Biophys Acta. 1775:76–91. 2007.
|
|
25
|
Shaw RJ, Hall GL, Lowe D, Bowers NL,
Liloglou T, Field JK, Woolgar JA and Risk JM: CpG island
methylation phenotype (CIMP) in oral cancer: Associated with a
marked inflammatory response and less aggressive tumour biology.
Oral Oncol. 43:878–886. 2007. View Article : Google Scholar : PubMed/NCBI
|
